XTSXGENX
Market cap10mUSD
, Last price
CAD
Name
Genix Pharmaceuticals Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
%
Shrs. gr., 5y
9.56%
Rev. gr., 5y
-50.61%
Revenues
12k
Net income
-4m
L+309.27%
CFO
-221k
L+0.50%
Profile
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and drops. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | 2016‑10 | 2015‑10 | |
| Income | |||||||||
Revenues | 12 | ||||||||
Cost of revenue | 288 | 998 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (276) | (998) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 12 | ||||||||
Tax Rate | |||||||||
NOPAT | (276) | (1,011) | |||||||
Net income | (4,396) 309.27% | (1,074) -35.01% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 512 | 183 | |||||||
Long-term debt | 5 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 500 | 178 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (221) | (220) | |||||||
CAPEX | (3) | ||||||||
Cash from investing activities | (3) | ||||||||
Cash from financing activities | 223 | 93 | |||||||
FCF | (267) | (869) | |||||||
| Balance | |||||||||
Cash | 12 | 9 | |||||||
Long term investments | |||||||||
Excess cash | 11 | 9 | |||||||
Stockholders' equity | (2,430) | 3,199 | |||||||
Invested Capital | 1,804 | 3,372 | |||||||
ROIC | |||||||||
ROCE | 44.03% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 59,224 | 59,224 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 272 | (434) | |||||||
EV/EBITDA | |||||||||
Interest | 52 | 12 | |||||||
Interest/NOPBT | |||||||||